Insight | Lyme borreliosis vaccines

Lyme vaccines: efficacy shown, Europe filed, and now the demand question.

Pfizer and Valneva's LB6V (PF-07307405) has delivered 73.2% efficacy in a 9,437-participant Phase 3, taken new data to IDWeek 2026, and has an EU application under EMA assessment. What no company has published is what that means for demand. VacZine Analytics has built it: a granular North American demand model, complete as of October 2026, with a European analysis in preparation.

From VacZine Analytics MarketVIEW: Lyme Borreliosis Vaccines (VAMV024). Analysis current October 2026.

73.2%
vaccine efficacy, VALOR
primary analysis after dose 4
9,437
participants aged 5+
in North America and Europe
EMA
EU application validated
14 August 2026
2045
North American model horizon
complete October 2026
Where the field stands

Twenty-four years after withdrawal, a vaccine is at the regulator's door

LYMErix left the market in 2002 and no Lyme vaccine has been licensed since. VALOR changed that picture: a global, placebo-controlled Phase 3 that showed clear efficacy, narrowly missed its formal statistical bar on the confidence interval, and was nonetheless taken into regulatory review in Europe. The United States filing is guided for the second half of 2026.

Lyme disease vaccines: from withdrawal to the filing windowWhere the field stands, October 20262002LYMErix withdrawnThe only previously licensedLyme vaccine leaves the market2022-2025VALOR in the fieldPhase 3 across three Lyme seasons,9,437 participants aged 5 and over23 Mar 2026Topline: 73.2% efficacyLower bound of the interval just shortof the pre-set success criterion14 Aug 2026EMA validates the filingEU marketing authorisation applicationnow under formal assessment22 Oct 2026Data at IDWeek 2026Pfizer and Valneva present thePhase 3 results in Washington, DC2H 2026US filing expectedBLA submission guided for thesecond half of 20262027Earliest launch windowRegulatory decisions guided withintwelve months of filingThe commercial question has changed.It is no longer whether a Lyme vaccine can work. It is how many people will get it, where, and at what net price.Source: Pfizer/Valneva announcements and presentations; VacZine Analytics MarketVIEW VAMV024vaczine-analytics.com
Public timeline. Filing and launch dates are company guidance and may change. Green = achieved; gold outline = expected.
The pointA first Lyme vaccine in over two decades is now a planning scenario, not a hypothetical. Teams that model it early set the terms for access, pricing and portfolio decisions.
New this month

IDWeek 2026: the data support the filing - and point to the booster question

The Phase 3 results were presented in Washington, DC this week. Three signals matter commercially: efficacy that is real and measurable, a tolerability profile that does not get in the way of a broad age range, and a protection pattern that rewards completing the course - and fades without further doses. That last point is a demand driver, not a footnote.

What the IDWeek 2026 data adds - in three signalsOral presentation, Washington DC, 22 Oct 2026 - summarised, not reproduced1 EfficacyCases after dose 42 SafetyTolerability profile3 Protection over timeEfficacy by Lyme season4Vaccine15Placebo73.2%vaccine efficacy (primary analysis)Confirmed Lyme disease casesafter the fourth doseWell toleratedMostly mild to moderate,self-limited reactionsBalancedAdverse events broadly inline with placeboNo surprisesNo unexpected findingsreportedSafety is a gating factor for avaccine aimed at ages 5 and over44.3%Season 1after dose 373.2%Season 2after dose 418.6%Season 3no further doseEfficacy built with the course,then fell once doses stoppedPoint estimates; intervals are wide.Directionally: booster policy matters.Source: Pfizer/Valneva presentation, IDWeek 2026 (selected points, redrawn); VacZine Analytics interpretationvaczine-analytics.com
Selected points redrawn from the company presentation; see the original for full data, intervals and caveats. Season 3 reflects a subset followed without further vaccination.
Figures are selected and redrawn from the Pfizer and Valneva presentation (IDWeek 2026, Washington DC) and carry the wide confidence intervals of an event-driven trial. They are shown here as context only; the full presentation remains the authority.
The analysis

A ground-up North American demand model - complete, and not easy to rebuild

Lyme risk is intensely local, and so is demand for a Lyme vaccine. We have therefore built a purpose-designed model for the United States and Canada rather than one generic forecast. It forecasts doses and net revenue from launch to 2045 for ages 5 and over, and it is built to be interrogated: every input is sourced or stated as an assumption, with sensitivity testing across the key drivers.

North American demand model: what the analysis coversCoverage shown; construction reserved for clientsVAMV024Lyme demandUnited States and CanadaLaunch to 2045Ages 5 and overMultiple exposure poolsBuilt from people genuinely at riskSub-state resolutionLyme risk is not uniform within a stateFour recommendation scenariosEach with its own demand trajectoryTraveller componentsDemand a local view would missCompeting-intervention overlayTests uptake dampening by an alternativeLayered payer mix and pricingMultiple price cases to net revenueCourse and booster dynamicsVolume reflects the full dosing scheduleComplete - October 2026Delivered as an executive presentation and a client-ready Excel model. Every input sourced or stated as an assumption, with sensitivity testing.Source: VacZine Analytics MarketVIEW - Lyme Borreliosis Vaccines (VAMV024)vaczine-analytics.com
Coverage of the completed North American model. Methods, inputs and outputs are reserved for licensed clients.
ReservedAbsolute doses, net revenue and scenario outcomes are available to clients under the MarketVIEW report. Request a briefing to see how the scenarios play out.
Two markets

The United States is modelled; Europe is next, and you can help shape it

The same vaccine meets very different markets. The North American analysis is ready now. A separate European analysis is being scoped, and its country coverage, depth and timing will be set with clients - so early conversations directly influence what is built.

One vaccine, two markets, two different questionsWhere each regional analysis standsUnited States and CanadaNorth American demand modelComplete - October 2026Large, local burden~476,000 people diagnosed and treated each year(CDC estimate); risk varies sharply by placeFiling expectedUS BLA guided for the second half of 2026under FDA Fast Track; launch window from 2027Demand turns on policy and accessRecommendation outcomes and payer coveragewill shape uptake as much as approval doesThe report answersHow big could demand be, and what moves it?How exposed is net revenue to policy and price?What does the full dosing course mean for volume?EuropeEuropean demand analysisIn preparationA burden hidden by under-reporting~132,000 cases reported to surveillance each year;company estimates run about three times higherFiling under assessmentEMA validated the EU filing on 14 Aug 2026;assessment under way, PRIME designationOne authorisation, many national decisionsCountry coverage, depth and timing will beshaped with clients - early input countsThe report answersWhere should a European launch start?Which countries carry the early opportunity?Register interest to help set the scope.Source: CDC; ECDC and national surveillance; Pfizer/Valneva (IDWeek 2026); VacZine Analytics MarketVIEW VAMV024vaczine-analytics.com
Burden figures are published estimates; European estimate from company presentation. Regulatory and launch timing are company guidance.
Why this matters now

Questions the report lets you answer before the market does

1
How large could demand be - and what could change it?Policy outcomes, access and price, tested scenario by scenario.
2
Where is the commercial upside concentrated?Lyme risk is local; the model is built to follow it.
3
What does the full dosing course mean for volume?Booster dynamics, not first doses alone.
4
What if a competing prevention option arrives?An overlay tests how uptake could be dampened.
5
How should we plan for Europe?Register interest and help set the scope of the European analysis.
6
What would a launch decision look like in our P&L?Multiple price cases converted to net revenue through detailed payer-mix inputs.
VacZine Analytics | MarketVIEW: Lyme Borreliosis Vaccines (VAMV024)

The North American model is ready now

This insight shows the shape and depth of the analysis; the figures and scenario outcomes are reserved for clients. Book a briefing to walk through the scenarios, or register your interest in the European analysis to help shape its scope.

View the report page Request a briefing Register interest in Europe